CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive: The comprehensive review by Khanna et al [15] summarized that CIP2A overexpression is found in almost all solid cancers and in some hematological malignancies such as acute and chronic myeloid leukemia, and that high expression of CIP2A has been proposed as a useful biomarker that predicts therapeutic response to chemotherapeutics such as doxorubicin, cisplatin, bortezomib, erlotinib, Checkpoint Kinase 1 inhibitors and pro-senescence based therapies such as vinka alkaloids chemotherapy and several in development small molecules [15, 17, 18].